REstoring Metabolic FLEXibility Through Combined Exercise in Breast Cancer Survivors: A Randomized Controlled Trial.
NCT07405385 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2026-05-28
Summary
The REFLEX study is a randomized, controlled clinical trial designed to evaluate the impact of a 16-week supervised, combined exercise program on metabolic flexibility and cardiorespiratory fitness in breast cancer survivors. While cancer treatments have significantly improved survival rates, the disease and its therapies often cause systemic mitochondrial dysfunction and muscle loss. This leads to persistent "metabolic inflexibility"-a reduced ability to efficiently switch between burning carbohydrates and fats for energy. This inflexibility, exacerbated by sedentary behavior and cancer-related fatigue, can severely diminish a patient's functional autonomy and overall quality of life. The trial focuses on assessing whether exercise can restore this metabolic adaptability in women aged 18 to 70 with stage I-III breast cancer who are currently on hormonal treatment and completed neo/adjuvant chemotherapy within the past 6 months.
The study operates on the primary hypothesis that an individualized exercise intervention will significantly improve the participants' metabolic flexibility-measured via the metabolic crossover point-and overall aerobic capacity (VO2max) when compared to a control group. Additionally, the trial will analyze secondary outcomes, including changes in cardiovascular and metabolic risk factors, muscle strength, body composition (such as bone mineral density), and patient-reported outcomes assessing quality of life, fatigue, joint pain, anxiety, and depression.
A total of 44 participants will be randomly assigned to either the intervention or control group. Participants in the intervention group will complete a 16-week program consisting of two weekly supervised sessions. Each session lasts between 55 and 85 minutes and includes a tailored combination of aerobic and strength training based on the individual's baseline fitness and metabolic thresholds. Participants in the control group. will receive standard educational materials via email, featuring healthy lifestyle and exercise guidelines from the World Health Organization (WHO) and the American College of Sports Medicine (ACSM).
To evaluate the program's effectiveness, comprehensive medical and functional assessments will be conducted at baseline, immediately after the 16-week intervention, and at a 3-month follow-up. These evaluations include submaximal and maximal exercise tests on a cycle ergometer to analyze respiratory gases, detailed blood tests, body composition imaging (DXA scans), and maximum dynamic strength testing. Ultimately, the research aims to generate high-quality evidence to optimize standard exercise recommendations for breast cancer survivors and improve their long-term health and resilience.
Conditions
- Cancer
- Breast Cancer
- Neoplasm
- Metabolic Flexibility
Interventions
- BEHAVIORAL
-
Control
Participants assigned to the control group receive standard care typically provided to patients in this phase of recovery. Instead of a supervised exercise program, these individuals are sent educational materials via email. This material consists of a video and official documents containing basic guidelines and recommendations for a healthy lifestyle, based on standards from the World Health Organization (WHO) and the American College of Sports Medicine (ACSM) for cancer survivors. The documents provide general instructions on physical activity, reducing sedentary behavior, and maintaining overall health habits. Like the intervention group, participants in the control group undergo all clinical and functional evaluations at the start of the study, after 16 weeks, and during a 3-month follow-up.
- BEHAVIORAL
-
Exercise
The intervention consists of a supervised, in-person, combined exercise program lasting 16 consecutive weeks, conducted at a specialized exercise unit. Participants attend two sessions per week, with at least 48 hours of recovery between sessions, and each session lasts between 55 and 85 minutes. The program follows a "combined" methodology, meaning every session integrates both resistance (strength) and aerobic training. To ensure safety and precision, sessions are led by a graduate in Physical Activity and Sport Sciences with specialized training in oncology, and participants work in small groups of 6 to 8 people. Each session is structured into four distinct parts: a 10-minute warm-up involving low-to-moderate intensity activity and joint mobility; a resistance training block; an aerobic training block; and a cool-down featuring static stretching for 30-40 seconds per muscle group. The resistance training portion utilizes a "full body" approach.
Sponsors & Collaborators
-
University of Castilla-La Mancha
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-30
- Primary Completion
- 2027-08-31
- Completion
- 2027-12-31
Countries
- Spain
Study Locations
More Related Trials
-
Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.
NCT03027063 ·Status: COMPLETED ·Phase: NA
-
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
NCT05078190 ·Status: ACTIVE_NOT_RECRUITING
-
Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer
NCT01572883 ·Status: COMPLETED
-
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
NCT04962425 ·Status: UNKNOWN
-
CARDIOCARE Prospective Clinical Study
NCT06334445 ·Status: RECRUITING
-
CARdiac Function Evaluation in Breast Cancer Patients
NCT03266809 ·Status: COMPLETED
-
MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study
NCT01246856 ·Status: UNKNOWN
-
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
NCT05732051 ·Status: RECRUITING ·Phase: PHASE2
-
Exercise for Ameliorating Chemotherapy Cardiotoxicity
NCT06595316 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects
NCT03131024 ·Status: COMPLETED ·Phase: NA
-
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients
NCT00806507 ·Status: COMPLETED
-
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
NCT00485979 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
NCT04961307 ·Status: UNKNOWN
-
Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
NCT06282796 ·Status: RECRUITING
-
Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy
NCT05019365 ·Status: UNKNOWN
-
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
NCT01301040 ·Status: TERMINATED ·Phase: PHASE2
-
JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
NCT06930521 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
NCT00944047 ·Status: COMPLETED ·Phase: PHASE2
-
Cardiotoxicity of Adjuvant Trastuzumab
NCT00858039 ·Status: COMPLETED
-
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
NCT00875238 ·Status: COMPLETED
-
Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
NCT06387901 ·Status: RECRUITING
-
Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves
NCT05584163 ·Status: UNKNOWN ·Phase: NA
-
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
NCT00436566 ·Status: COMPLETED ·Phase: PHASE2
-
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
NCT04305613 ·Status: ACTIVE_NOT_RECRUITING
-
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
NCT02102438 ·Status: WITHDRAWN ·Phase: NA